More on COCP’s quest for a shorter HCV regimen: https://globenewswire.com/news-release/2018/10/08/1617926/0/en/Cocrystal-Pharma-Announces-Clinical-Trial-Agreement-for-Investigator-Initiated-Phase-2a-Study-in-Hong-Kong-of-CC-31244-for-Ultra-Short-Treatment-of-Hepatitis-C-Virus.html This is a single-arm IST in Hong Kong.